Search the Newsreel

Analyst Estimates: Here's What Brokers Think Of BridgeBio Pharma, Inc. (NASDAQ:BBIO) After Its Second-Quarter Report

This article analyzes what brokers think of BridgeBio Pharma, Inc. (NASDAQ:BBIO) following its second-quarter report. It would likely detail analyst ratings, price targets, and any changes in sentiment post-earnings, providing insights into the company's financial performance and future outlook from an investment perspective.

BridgeBio Pharma Announces Pricing of Oversubscribed Secondary Offering that Diversifies its Institutional Shareholder Base

BridgeBio Pharma, Inc. announced the pricing of an oversubscribed secondary offering of 5,000,000 shares of its common stock by KKR Genetic Disorder L.P. The company itself is not selling shares and will not receive any proceeds from the offering. This transaction aims to further …

KKR to Sell 5M BridgeBio Shares; Company Receives No Proceeds

BridgeBio Pharma announced the pricing of a secondary offering of 5,000,000 shares of its common stock by existing shareholder KKR Genetic Disorder L.P. BridgeBio will not issue any shares or receive any proceeds from this transaction, which is expected to close on August 17, …

BridgeBio Pharma (BBIO) holders to resell 5M shares in $390M offering

BridgeBio Pharma is facilitating a secondary offering where a KKR-affiliated selling stockholder will sell 5,000,000 shares of common stock at $78.00 per share, totaling $390 million. BridgeBio Pharma will not receive any proceeds from this transaction, as all net proceeds will go to the …

BridgeBio Pharma Announces Launch of Secondary Offering of Common Stock on Behalf of an Existing Shareholder

BridgeBio Pharma, Inc. (Nasdaq: BBIO) has announced a secondary public offering of 5,000,000 shares of its common stock by KKR Genetic Disorder L.P., an existing shareholder. BridgeBio itself is not selling any shares and will not receive any proceeds from this offering. William Blair, …

KKR Proposes Sale of 5 Million BridgeBio Pharma Shares in Offering

BridgeBio Pharma (BBIO) announced a secondary public offering of 5,000,000 shares of its common stock, to be sold by existing shareholder KKR Genetic Disorder L.P. BridgeBio will not sell any shares in this transaction and will not receive any proceeds. The offering is subject …

Analysts Have Made A Financial Statement On BridgeBio Pharma, Inc.'s (NASDAQ:BBIO) Second-Quarter Report

BridgeBio Pharma Inc. (NASDAQ:BBIO) saw its shares rise 2.3% after its second-quarter report, with revenues of US$244m beating expectations but statutory losses widening to US$0.78 per share. Analysts have updated their forecasts, projecting US$1.01b in revenues for 2026, a 42% increase, while expecting losses …

BBIO Stock Price Prediction 2025-2026 | BridgeBio Pharma Inc Forecast

BridgeBio Pharma (NASDAQ:BBIO) Price Target Raised to $111.00

JPMorgan Chase & Co. has increased its price target for BridgeBio Pharma (NASDAQ:BBIO) to $111.00 from $100.00, maintaining an "overweight" rating and suggesting a 32.73% potential upside. This comes as the company's Q2 revenue significantly beat estimates, growing 120.4% year-over-year to $243.68 million, despite …

Canaccord raises BridgeBio Pharma stock price target on revenue beat

Tema ETFs LLC Trims Stock Position in BridgeBio Pharma, Inc. $BBIO

Tema ETFs LLC significantly reduced its stake in BridgeBio Pharma, Inc. by 32.2% in the second quarter, selling 36,197 shares but still retaining 76,076 shares valued at $5.67 million. Despite institutional investors owning 99.85% of BBIO and a consensus "Moderate Buy" rating with a …

BridgeBio Pharma (BBIO) Stock Rally Leans On Attruby As Losses Recede

BridgeBio Pharma's stock saw a modest pullback despite strong Q2 2026 results driven by significant revenue from its flagship drug Attruby, which accounted for the majority of its $243.7 million quarterly revenue. While losses narrowed and pipeline milestones were achieved, concerns remain about the …

BridgeBio Earnings: Strong Attruby Uptake as Late-Stage Candidates Are Under Regulatory Review

BridgeBio’s 56 New Employees Get Awards With Vesting Starting in 2027

BridgeBio Pharma announced equity inducement grants of 66,705 restricted stock units to 56 new employees, with the first quarter vesting on August 16, 2027. These grants are part of an employment inducement plan under Nasdaq Listing Rule 5635(c)(4). The company aims to develop transformative …

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BridgeBio Pharma, Inc. PALO ALTO, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that on August 8, 2026, the compensation committee of BridgeBio's board …

Bank of America Forecasts Strong Price Appreciation for BridgeBio Pharma (NASDAQ:BBIO) Stock

BridgeBio Pharma, Inc. Stock 12‑Month Price Target Raised to $109.44, Implies 29% Upside

BridgeBio Pharma, Inc.'s stock (BBIO) has seen its average 12-month price target raised from $107.65 to $109.18 by 19 analysts, implying a potential 29% upside from its Aug. 10 closing price. The consensus rating for BBIO remains a "Buy" among 23 analysts, with 21 …

BridgeBio: Attruby Delivers In Q2, Expect Three New Launches In 12 Months (NASDAQ:BBIO)

BridgeBio Pharma reported strong Q2 results, exceeding analyst expectations and reaffirming its guidance for Attruby/Beyonttra global sales to surpass $1 billion this year. The company saw a significant surge in Attruby's U.S. net sales and increased Beyonttra royalties, indicating growing market share. BridgeBio's recent …

BridgeBio Q2 Earnings Miss, Revenues Beat as Attruby Sales Surge

BridgeBio Pharma (BBIO) reported a wider-than-expected Q2 2026 loss of 78 cents per share but saw revenues surge 120% year over year to $243.7 million, beating estimates, primarily driven by strong sales of its drug Attruby. The company is also advancing multiple late-stage pipeline …

BridgeBio Pharma (NASDAQ:BBIO) Stock Price Expected to Rise, TD Cowen Analyst Says

Morgan Stanley Has Lowered Expectations for BridgeBio Pharma (NASDAQ:BBIO) Stock Price

BRIDGEBIO PHARMA, INC. : TRUIST SECURITIES RAISES TARGET PRICE TO $107 FROM $102

Truist Securities has increased its target price for BridgeBio Pharma, Inc. (BBIO.O) from $102 to $107. The news was reported by Reuters. This adjustment reflects an updated outlook on the company's valuation by the financial institution.

Wells Fargo raises BridgeBio Pharma stock price target on launch outlook

Wells Fargo has increased its price target for BridgeBio Pharma (NASDAQ:BBIO) to $102 from $98, maintaining an Overweight rating due to anticipated near-term launches. Despite an 11% year-to-date gain, the stock is considered slightly overvalued. The firm expects further upside after detailed CARDIO-Transform data …

Quantinno Capital Management LP Purchases 21,464 Shares of BridgeBio Pharma, Inc. $BBIO

Quantinno Capital Management LP significantly increased its stake in BridgeBio Pharma, Inc. by 199.2% in the first quarter, adding 21,464 shares to reach a total of 32,240 shares valued at $2.39 million. This move is part of broader institutional investment, with firms like Janus …

BridgeBio Pharma Inc (BBIO) (Q2 2026) Earnings Call Highlights: Attruby Surges 211% as Pipeline ...

This article first appeared on GuruFocus. Total Revenues: $243.7 million for Q2 2026, compared to $110.6 million in Q2 2025. Attruby Net Product Revenue: $222.4 million, up from $71.5 million in the same period last year. Royalty Revenue: Increased to $15.4 million from $1.6 …

BridgeBio outlines three launches with first PDUFA set for November 27, 2026 and RECLAIM-HP readout in next 18 months

Earnings Call Insights: BridgeBio Pharma (BBIO) Q2 2026 MANAGEMENT VIEW * CEO Neil Kumar framed Q2 as a turning point, saying, "it feels like we're at T=0 in BridgeBio's next chapter," and tied near-term value creation to Attruby’s next phase, adding, "the combination of …

BridgeBio Pharma (NASDAQ:BBIO) Announces Earnings Results

BridgeBio Pharma (BBIO) Reports Q2 Loss, Tops Revenue Estimates

BridgeBio Pharma (BBIO) came out with a quarterly loss of $0.78 per share versus the Zacks Consensus Estimate of a loss of $0.64. This compares to a loss of $0.95 per share a year ago. These figures are adjusted for non-recurring items. This quarterly …

BridgeBio Pharma (NASDAQ: BBIO) grows Q2 2026 revenue but carries heavy debt load

BRIDGEBIO PHARMA ($BBIO) Releases Q2 2026 Earnings

This article first appeared on GuruFocus. Total Revenues: $243.7 million for Q2 2026, compared to $110.6 million in Q2 2025. Attruby Net Product Revenue: $222.4 million, up from $71.5 million in the same period last year. Royalty Revenue: Increased to $15.4 million from $1.6 …

BridgeBio Pharma 2026: Revenue $243.68M, EPS ($0.78) — 10-Q Summary

BridgeBio Pharma reported its 2026 quarterly results, showing a significant increase in revenue to $243.68M from $110.57M in the prior year. Despite the revenue growth, the company recorded a net loss of ($152.22M) and a diluted loss per share of ($0.78), though these figures …

Earnings Flash (BBIO) BridgeBio Pharma, Inc. Reports Q2 Revenue $243.7M, vs. FactSet Est of $220.9M

BridgeBio Pharma, Inc. (BBIO) reported its Q2 revenue of $243.7 million, surpassing the FactSet estimate of $220.9 million. The company's stock, traded on Nasdaq, saw a slight increase of 0.22% on August 10, 2026, with year-to-date growth of 10.69%. BridgeBio Pharma focuses on developing …

BridgeBio Reports Second Quarter 2026 Financial Results and Corporate Updates

BridgeBio Pharma, Inc. - $243.7 million in total second quarter revenues, primarily comprised of $222.4 million of U.S. Attruby® net product revenue, with growth led by the treatment-naïve segment as physicians increasingly start and keep patients on Attruby - Attruby is the first ATTR-CM …